4.6 Article

The course of pain and dysphagia after radiofrequency ablation for Barrett's esophagus-related neoplasia

期刊

ENDOSCOPY
卷 55, 期 3, 页码 255-260

出版社

GEORG THIEME VERLAG KG
DOI: 10.1055/a-1929-1448

关键词

-

向作者/读者索取更多资源

This study aimed to describe the course of pain and dysphagia after radiofrequency ablation (RFA) treatment for Barrett's esophagus (BE) neoplasia and identify associated risk factors. The results showed that 95% of patients reported post-RFA pain, with 64% experiencing major pain. Dysphagia was present in 83% of patients.
Background Radiofrequency ablation (RFA) is effective for eradication of Barrett's esophagus (BE) neoplasia, but little is known on the course of pain and dysphagia after RFA. We aimed to describe the course of post-RFA symptoms and to identify possible associated risk factors. Methods In this multicenter, observational cohort study. all RFA procedures registered in a prospective database were included. Patient and treatment characteristics were collected from medical records and patients self-registered post-procedural symptoms in electronic symptom diaries for 14 days. Mixed model regression was used for the analyses. Results In total, 255 diaries were completed. Post-RFA pain was reported for 95% (95 %Cl 93-98) of procedures (median duration 14 days; 25th-75th percentiles [p25-p75] 11-14) and major pain for 64% (95 %CI 58-69; median duration 8 days, p25-p75 3-13). Post-procedural pain significantly increased with BE length, younger age, and no prior ablation. Dysphagia was present after 83% (95 %CI 79-88) of procedures (median duration 13 days, p25-p75 9-14). The risk of dysphagia decreased with age and increased when patients experienced more pain. Conclusions RFA treatment for BE-related neoplasia seems a significant burden for patients, and post-procedural symptoms should be taken into account when counseling patients before starting endoscopic eradication therapy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据